

# Michael A Curran

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9573332/michael-a-curran-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49  
papers

3,873  
citations

24  
h-index

54  
g-index

54  
ext. papers

4,879  
ext. citations

9.8  
avg, IF

5.5  
L-index

#	Paper	IF	Citations
49	PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 4275-80	11.5	1276
48	CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. <i>Journal of Clinical Investigation</i> , <b>2006</b> , 116, 1935-45	15.9	531
47	Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. <i>JCI Insight</i> , <b>2016</b> , 1,	9.9	226
46	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1388-1396	12.9	199
45	Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. <i>PLoS ONE</i> , <b>2011</b> , 6, e19499	3.7	168
44	Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 5137-5149	15.9	159
43	4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 117	5.3	153
42	Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. <i>Nature Immunology</i> , <b>2019</b> , 20, 835-851	19.1	147
41	Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 743-55	16.6	111
40	Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. <i>Cancer Research</i> , <b>2009</b> , 69, 7747-55	10.1	101
39	Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. <i>Cancer Immunology Research</i> , <b>2017</b> , 5, 676-684	12.5	91
38	Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, E5290-9	11.5	59
37	PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8 T-Cell-Driven Antitumor Immunity. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2383-2394	12.9	50
36	Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. <i>Nature Communications</i> , <b>2017</b> , 8, 1447	17.4	48
35	Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 180-194	1	37
34	Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1138-1151	12.9	36
33	Immune checkpoint combinations from mouse to man. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 885-92	7.4	33

32	Prolonged liver-specific transgene expression by a non-primate lentiviral vector. <i>Biochemical and Biophysical Research Communications</i> , <b>2004</b> , 320, 998-1006	3.4	32
31	Evofofosamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	31
30	New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation. <i>Annual Review of Medicine</i> , <b>2019</b> , 70, 409-424	17.4	30
29	Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF- $\kappa$ B signaling improves the efficacy of immunotherapy in a brain cancer model. <i>Neurotherapeutics</i> , <b>2012</b> , 9, 827-43	6.4	29
28	TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma <b>2019</b> , 7, 323		29
27	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1368-1397	24.4	27
26	Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV oral cancer <b>2019</b> , 7, 252		25
25	Efficient transduction of pancreatic islets by feline immunodeficiency virus vectors1. <i>Transplantation</i> , <b>2002</b> , 74, 299-306	1.8	23
24	Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3003-3003	2.2	21
23	Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	16
22	Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2019</b> , 29, 126640	2.9	15
21	Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV Oral Cancers. <i>Cancer Research</i> , <b>2018</b> , 78, 5327-5339	10.1	15
20	Prolonged transgene expression in murine salivary glands following non-primate lentiviral vector transduction. <i>Molecular Therapy</i> , <b>2005</b> , 12, 137-43	11.7	14
19	Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	14
18	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	14
17	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. <i>Cancer Immunology Research</i> , <b>2020</b> , 8, 1365-1380	12.5	13
16	MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. <i>Oncotarget</i> , <b>2020</b> , 9, 1846915	7.2	12
15	Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4325-4337	12.9	12

14	Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". <i>Immunobiology</i> , <b>2012</b> , 217, 590-2	3.4	9
13	Retrovirally transferred genes inhibit apoptosis in an insulin-secreting cell line: implications for islet transplantation. <i>Cell Transplantation</i> , <b>2004</b> , 13, 489-96	4	9
12	Tumor hypermetabolism confers resistance to immunotherapy. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 65, 155-163	12.7	7
11	Protection of human pancreatic islets using a lentiviral vector expressing two genes: cFLIP and GFP. <i>Cell Transplantation</i> , <b>2008</b> , 17, 793-802	4	7
10	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3050-3060	12.9	7
9	High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege <b>2021</b> , 9,		7
8	Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , <b>2021</b> , 8, 1195-1207	5.3	6
7	mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1). <i>ACS Chemical Biology</i> , <b>2020</b> , 15, 1630-1641	4.9	5
6	Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. <i>PLoS ONE</i> , <b>2012</b> , 7, e35222	3.7	4
5	EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy <b>2019</b> , 7, 5		4
4	Preclinical Data Supporting Antitumor Activity of PD-1 Blockade. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2018</b> , 24, 2-6	2.2	3
3	Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5528-5535	12.9	2
2	ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. <i>Science Immunology</i> , <b>2022</b> , 7,	2.8	2
1	Method of long-term, recurrent, intracerebroventricular infusion of cellular therapy in mice.. <i>Journal of Neuroscience Methods</i> , <b>2022</b> , 371, 109529	3	